APN、TNF-α及Fibroscan受控衰减参数在非酒精性脂肪肝中的变化

Changes of APN,TNF-αand fibroscan controlled attenuation parameters in patients with non-alcoholic fatty liver disease

目的分析布拉氏酵母菌治疗对非酒精性脂肪肝患者脂联素(APN)、肿瘤坏死因子-α(TNF-α)及Fibroscan(FS)受控衰减参数的影响。方法选取2019年12月至2020年12月本院100例非酒精性脂肪肝患者作为研究对象,根据干预方案的差异分为研究组(生活及行为方式的干预+布拉氏酵母菌,n=53)和对照组(仅进行生活及行为方式的干预,n=47)。比较两组治疗前后肝功能、APN、炎性因子、可控衰减参数(CAP)、血脂及体质指数(BMI)水平差异。结果治疗后,两组的肝功能和APN均有所改善,研究组的TBIL和DBIL水平较对照组低,APN、ALB、PTA水平较对照组高,差异均具有统计学意义(P<0.05)。治疗后研究组TNF-α、IL-6均低于对照组,IL-10高于对照组,差异均具有统计学意义(P<0.05)。治疗后研究组TG、HDL-C、LDL-C水较治疗前及对照组低,差异具有统计学意义(P<0.05)。治疗后两组CAP、BMI均降低,且研究组低于对照组,差异均具有统计学意义(P<0.05)。结论布拉氏酵母菌可改善非酒精性脂肪肝患者肝功能,降低炎症因子含量,调节其血脂、BMI和CAP水平,值得推广。

Objective To analyze the effect of Saccharomyces boulardii treatment on adiponectin(APN),tumor necrosis factor-α(TNF-α)and fibroscan(FS)controlled attenuation parameters(CAP)in patients with non-alcoholic fatty liver disease.Method 100 patients with non-alcoholic fatty liver disease from December 2019 to December 2020 were selected and divided into the study group(intervention of life and behavior style+Saccharomyces boulardii,n=53)and the control group(only intervention of life and behavior style,n=47)according to the difference of intervention plan.The differences in liver functions,APN,inflammatory factors,controllable attenuation parameters(CAP),blood lipids and body mass index(BMI)before and after treatment were compared between 2 groups.Result After treatment,the liver function and APN between 2 groups improved(P<0.05).The levels of TBIL and DBIL in the study group were lower than those in the control group,and the levels of APN,ALB,and PTA were higher than those in the control group,the differences are statistically significant(P<0.05).After treatment,TNF-αand IL-6 in the study group were lower than those in the control group,and IL-10 was higher than that in the control group,the differences are statistically significant(P<0.05).After treatment,the levels of TG,CHOL and LDL-C in the study group were lower than those before treatment and lower than those in the control group,the differences are statistically significant(P<0.05).CAP and BMI of 2 groups decreased after treatment,and the level of the study group was lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion Saccharomyces boulardii can improve the liver function of patients with non-alcoholic fatty liver,reduce the levels of inflammatory factors,and regulate their blood lipids,BMI,and CAP levels.It is worthy of promotion.